New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
Stopped early · Not applicable
Conditions studied: Pancreatic Cancer
In brief
Bluestar Genomics has developed a non-invasive test that aids in detection of occult pancreatic cancer in patients with new onset type II diabetes (NOD) who are 50 years old or older. The purpose of this study is to evaluate the performance of Bluestar Genomics early-detection pancreatic cancer test in a clinical setting. The study is prospective, longitudinal and interventional; tests will be ordered and results returned to site-investigators. If the test returns a pancreatic cancer signal "detected" result the study participant will undergo MRI imaging to evaluate for the presence of pancreatic cancer. The study is planned to enroll 6,550 newly diagnosed type 2 diabetic subjects according to inclusion and exclusion criteria.
Key facts
- Study ID
- NCT05188586
- Run by
- ClearNote Health
- People needed
- 26
- Starts
- 2022-10-31
- Expected to finish
- 2023-03-16
- Last updated by the study team
- 2024-09-19
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ≥ 50 years of age or older at the time of enrollment
- Willing to sign the informed consent form
- Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):
- FBG ≥126mg/dl HbA1c ≥6.5% RBG ≥ 200mg/dl 2-hour post-glucose ≥200mg/dl (OGTT)
- Must have had glycemic parameter measured in 3-18 months prior to screening that did NOT meet DM criteria
- Must be willing to provide several tubes of blood without endangering health
- No history of pancreatic cancer or other known pancreatic neoplasia
- No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated > 1 year prior to enrollment and in situ cancers)
You may not qualify if…
- Prior DM diagnosis
- Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)
- Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment
- Any known pancreatic lesions (aside from diabetes)
- Received cancer treatment within the past 5 years (with the exception of treatment of non-melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.
- Current chronic or acute oral steroid use
- History of intra-articular steroid injections (<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)
- Any surgery requiring general anesthesia within 2 months of collection
- Local anesthetic (including dental novocaine) within 1 week of collection
- History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)
- Blood transfusion within 1 month
- Organ transplant recipient
- Currently pregnant, or pregnancy within last 12 months
- Receipt of systemic immunomodulation therapy within past 12 months
- Significant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions
Where it is running
- Headlands Research - Scottsdale - PPDS — Scottsdale, Arizona, United States
- JEM Research Institute - Headlands - PPDS — Atlantis, Florida, United States
- Prisma Health/Endocrinology specialist and Thyroid — Greenville, South Carolina, United States
- Consano Clinical Research, LLC — Shavano Park, Texas, United States
- Manassas Clinical Research Center — Manassas, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.